For the Inventor, By the Inventor

Enter assignee name

Hamilton, Bermuda

Irm LLC

USPTO Granted Patents = 152

% Expired Patents = 70.4

CIPO Patents = 10

EPO Patents = 46

Forward Citations = 1,733

Loading Chart...

Loading Chart...

284 inventors (with patents filed for the assignee):

Nathanael Schiander Gray (26 out of 175 patents)

Shifeng Pan (20 out of 31 patents)

Valentina Molteni (16 out of 39 patents)

4. Robert Charles Downs (15 out of 36 patents)

5. Yi Liu (14 out of 153 patents)

6. Arnab Kumar Chatterjee (14 out of 40 patents)

7. Juliet Nabakka (14 out of 19 patents)

8. Hong Liu (14 out of 20 patents)

9. Robert Epple (14 out of 18 patents)

10. David C Tully (14 out of 27 patents)

11. Yun He (13 out of 48 patents)

12. Jon Christopher Loren (13 out of 20 patents)

13. Phillip B Alper (13 out of 16 patents)

14. Xiaolin Li (12 out of 47 patents)

15. Qiang Ding (12 out of 24 patents)

Core Competencies:

Medical Data Management

Kinase Inhibitors

Cancer Therapies

GPR119 Modulators

Hedgehog Pathway Inhibitors

Epstein-Barr Virus

Protease Inhibitors

Stem Cell Expansion

Patient Information Security

TLR Modulators

Pulmonary Hypertension Treatments

Immunosuppressants

152 patents: Sort by Forward Citations

1. 12620475 - Intergrated medical management system for intergrating and managing data including data located on external servers (2026-05-05),

2. 11901075 - Method and apparatus for generating medical information of object (2024-02-13),

3. 11893124 - Method for building cloud-based medical image database for protection of patient information and reading medical image therefrom (2024-02-06),

4. 9592288 - Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate (2017-03-14),

5. 9045470 - Compounds and compositions as TLR activity modulators (2015-06-02),

6. 9023839 - Compounds and compositions as c-kit kinase inhibitors (2015-05-05),

7. 9023791 - Fibroblast growth factor 21 mutations (2015-05-05),

8. 8957081 - Compounds and compositions as protein kinase inhibitors (2015-02-17),

9. 8927281 - Method for expanding hematopoietic stem cells (2015-01-06),

10. 8883819 - Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension (2014-11-11),

11. 8871754 - Compounds and compositions for the treatment of parasitic diseases (2014-10-28),

12. 8859574 - Compounds and compositions as kinase inhibitors (2014-10-14),

13. 8722691 - Azolopyrimidines as inhibitors of cannabinoid 1 activity (2014-05-13),

14. 8710192 - PCSK9 antagonists (2014-04-29),

15. 8703787 - Methods of using ALK inhibitors (2014-04-22),

Company Overview

Irm LLC, based in Hamilton, Bermuda, specializes in innovative medical solutions with a focus on advancing cancer therapies and medical data management. The company is engaged in the development of kinase inhibitors, GPR119 modulators, and Hedgehog pathway inhibitors, aiming to address complex health challenges. Additionally, Irm LLC explores therapeutic avenues related to Epstein-Barr virus and protease inhibitors, while also contributing to stem cell expansion technologies, positioning itself at the forefront of medical innovation.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

152 Patents

#5 in Hamilton

#5 in Bermuda

#5,366 in the World

Hamilton, Bermuda

Irm LLC

Forward Citations = 1,733

284 inventors:

Nathanael Schiander Gray (26 out of 175 patents)

Shifeng Pan (20 out of 31 patents)

Valentina Molteni (16 out of 39 patents)

4. Robert Charles Downs (15 out of 36 patents)

5. Yi Liu (14 out of 153 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Irm LLC. Retrieved from https://idiyas.com/company/irm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…